GNRH1 and Familial prostate cancer: A more recent study, including 11 199 men with prostate cancer, of whom 229 had a venous thromboembolism after diagnosis, showed a greater risk of venous thrombosis associated with cyproterone acetate than with gonadrotropin releasing-hormone (GNRH) agonists or orchiectomy.7